About Actavis:-
Actavis Generic (formerly known as Watson Pharmaceuticals and Activis PLC, before the acquisition of Allergen Inc.) is a global pharmaceutical company that offers branded pharmaceuticals, generic and over-the-counter medicines, and biological products. Actavis is a professional presence in nearly 100 countries. The company has world headquarters in Dublin, Ireland, and is the administrative headquarters in United Jersey, New Jersey, Parsippany-Troy Hills.
Actavis PLC Markets, among the major therapeutic categories in brand products by six major franchises: Aesthetics / Dermatology / Plastic Surgery; Neurosis / CNS; Eye care women's health and kidney; GI and cystic fibrosis; And heart diseases and infectious diseases. The company's products include Botox, Namenda, Restasis, Linzes, Biostolic, Juvedram, Latis, Lou Lauestin Fay, Astres, Teflarro, Dlvance, Ozardex , natural, vibrad, lilata, sephriss, capable, actonel, androderm, gelnik and others.
Actavis PLC also works in the world's third largest generic business. The company has been ranked among the top 3, 16 global markets, five major and 33 global markets in 12 global markets. Actavis also developed generic pharmaceutical products outside the United States and did their Medicare third-party business, the world's largest generic pharmaceutical out-license business. Medicine has more than 300 customers worldwide and offers more than 200 products. Actavis plc is also developing biosymaler products in oncology and other therapeutic categories, and currently has five bio-chemical products developed. Actavis plc has more than 40 production and distribution facilities worldwide, with annual production of 40 billion units. In the Global operations of Actavis included Anda Inc., the fourth largest generic pharmaceutical product distributor in the United States.
On June 15, 2015, the activism plc changed its name to Olvergan PLC, but the company will continue to operate under the name of US and Canadian Generic Business Activis.
In July 2015, Orglan PLC announced that it would be sold to the company's generic distribution division Telan Pharmaceuticals for $ 40.5 billion, proposed transaction to complete in the first quarter of 2016.
History:-
In the spring of 1983, the company was established [19], when Alan Chao, along with colleagues, got funding from friends and family. And David Hissia, Ph.D. Launched a small drug development institute. Two months later, the founders established an initial production-development and analytical laboratory with six employees (with two founders) at Leased Space in Libertyville, Illinois (U.S.).
By the end of the same year, the company was moved to southern California in the initial 2,000-square-feet (190m2) leased facility in Corona and the development and production of generic drugs started. [20] Corona site rapidly became a corporate headquarters for the expanded US company.
